Brand name: ALIRUXOLITINIB
Composition:
Each tablet contains:
Ruxolitinib………………………………20mg.
Indications:
Indicated in the treatment of adult patients with disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (PMF) (also known as chronic idiopathic myelofibrosis), post-polycythemia-vera myelofibrosis (PPV-MF), or post-essential thrombocythaemia myelofibrosis (PET-MF), and patients with graft-vs-host disease.
Dosage:
Before starting treatment with this product, a full blood cell count, including a white blood cell classification count, must be performed. This product is administered orally and can be taken with or without food, use according to the physician’s guidance.
- Myelofibrosis:
- Greater than 200×109/L: 20 mg given orally twice daily.
- 100×109/L to 200×109/L: 15 mg given orally twice daily.
- 50×109/L to less than 100×109/L: 5 mg given orally twice daily.
- Monitoring blood tests every 2 to 4 weeks until levels stabilize, and observe any symptoms that occur during medication use to adjust the dosage and amount as appropriate.
- Polycythemia Vera:
- The starting dose of ALIRUXOLITINIB is 10 mg given orally twice daily.
- Acute Graft-Versus-Host Disease:
- The starting dose of ALIRUXOLITINIB is 5 mg given orally twice daily.
- Chronic Graft-Versus-Host Disease:
- The starting dose of ALIRUXOLITINIB is 10 mg given orally twice daily.
Contraindications:
• Patients who are allergic to this product.
• Pregnant and lactating women.
Warnings:
• Thrombocytopenia, anemia, and neutropenia may occur.
• Resolve bacterial infections before starting therapy with ALIRUXOLITINIB.
• Symptoms may worsen after interruption or discontinuation of dosing.
• May increase risk of developing skin cancer.
• Children should use with caution.
Adverse Effects:
• Decreased platelet count and anemia.
• Infection and edema.
Dosage form: White tablets.
Expiry date: 24 months from the date of manufacture.
Packaging: 56 tablets/bottle.
Storage:
• Store at room temperature 20-25℃.
• Keep out of reach of children.
DISCLAIMER
The information on this website about our medications is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay seeking care because of something you have read on this website.
For your safety:
Do not self-diagnose or treat any medical condition based solely on the information on this website. If you have any questions or concerns about a medication, please talk to your doctor or pharmacist.
